Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector

Gene Therapy

Volumn 9, Issue 9, 2002, Pages 537-546

  Ziller, C ^a   Stoeckel, F ^a   Boon, L ^b   Haegel Kronenberger, H ^a  

^a TRANSGENE S A   (France)

^b Tanox Pharma BV   (Netherlands)

Author keywords

Adenovirus vector; Costimulatory molecules; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BETA GLOBULIN; BLOOD CLOTTING FACTOR 9; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD80 MONOCLONAL ANTIBODY; CD86 ANTIGEN; CD86 MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA BINDING PROTEIN; GAMMA INTERFERON; GENE PRODUCT; GROWTH HORMONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN FUNCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; GENE THERAPY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRAL GENE DELIVERY SYSTEM; VIRUS VIRULENCE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CD40 LIGAND; FACTOR IX; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0036259052     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301684     Document Type: Article

References (51)

1. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
2. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
3. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
4. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
5. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
6. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
7. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA anti-bodies to adenovirus and beta-galactosidase
8. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response
9. Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts
10. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors
11. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a non-depleting CD4 antibody
12. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates
13. CD40 and CD154 in cell-mediated immunity
14. CD28/B7 system of T cell costimulation
15. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
16. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy
17. Regulation of self-tolerance by CD80/CD86 interactions
18. Role of interleukin 12 and costimulators in T cell anergy in vivo
19. Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production
20. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4
21. CTLA4 ligation blocks CD28-dependent T cell activation
22. Induction of peripheral tolerance in vivo requires CTLA4 engagement
23. The emerging role of CTLA4 as an immune attenuator
24. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28
25. The role of CD80, CD86 and CTLA4 in alloimmune responses and the induction of long-term allograft survival
26. Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation
27. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration
28. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver
29. Transient subversion of CD40 ligand function diminishes immune response to adenovirus vectors in mouse liver and lung tissues
30. Antibody to CD40L inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airways
31. Readministration of adenovirus vector in non-human primate lungs by blockade of CD40-CD40 ligand interactions
32. B7.1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
33. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: Application to autoimmune disease therapy
34. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
35. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+ T-cell responses
36. A negative regulatory function of B7 revealed in B7-1 transgenic mice
37. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57B1/6 mice
38. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade
39. Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: Involvement of cross-correction in widespread distribution of the gene products and long-term effects of CTLA4-Ig coexpression
40. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
41. The roles of CD28 and CD40 ligand in T cell activation and tolerance
42. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation
43. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells
44. Role of costimulators in T cell differentiation: Studies using antigen-presenting cells lacking expression of CD80 or CD86
45. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo
46. CTLA4-Ig and anti-CD40 ligand prevent allograft rejection in primates
47. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
48. Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity
49. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
50. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
51. Evaluation of the concentration and bioactivity of adenovectors for gene therapy